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Early Changes in the Serotype Distribution of Invasive 
Pneumococcal Isolates from Children after the Introduction of 
Extended-valent Pneumococcal Conjugate Vaccines in Korea, 
2011-2013
This study was performed to measure early changes in the serotype distribution of 
pneumococci isolated from children with invasive disease during the 3-year period 
following the introduction of 10- and 13-valent pneumococcal conjugate vaccines (PCVs) 
in Korea. From January 2011 to December 2013 at 25 hospitals located throughout Korea, 
pneumococci were isolated among children who had invasive pneumococcal disease (IPD). 
Serotypes were determined using the Quellung reaction, and the change in serotype 
distribution was analyzed. Seventy-five cases of IPD were included. Eighty percent of 
patients were aged 3-59 months, and 32% had a comorbidity that increased the risk of 
pneumococcal infection. The most common serotypes were 19A (32.0%), 10A (8.0%), and 
15C (6.7%). The PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, and 6A) accounted for 
14.7% of the total isolates and the PCV13 minus PCV7 types (1, 3, 5, 7F, and 19A) 
accounted for 32.0% of the total isolates. Serotype 19A was the only serotype in the 
PCV13 minus PCV7 group. The proportion of serotype 19A showed decreasing tendency 
from 37.5% in 2011 to 22.2% in 2013 (P = 0.309), while the proportion of non-PCV13 
types showed increasing tendency from 45.8% in 2011 to 72.2% in 2013 (P = 0.108). 
Shortly after the introduction of extended-valent PCVs in Korea, serotype 19A continued 
to be the most common serotype causing IPD in children. Subsequently, the proportion of 
19A decreased, and non-vaccine serotypes emerged as an important cause of IPD. The 
impact of extended-valent vaccines must be continuously monitored.
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INTRODUCTION
Streptococcus pneumoniae is a leading cause of invasive bacterial infection in children. 
The invasiveness and antibiotic resistance pattern of pneumococcus vary according to 
serotype (1). After the introduction of the 7-valent pneumococcal conjugate vaccine 
(PCV7, Prevnar, Wyeth, Collegeville, PA, USA), the annual incidence of invasive pneu-
mococcal disease (IPD) caused by the PCV7 serotypes decreased. However, replace-
ment by non-PCV7 serotypes has been observed, and pneumococcus has caused sig-
nificant morbidity despite the reduction of PCV7-type IPD. In 2010, a 13-valent conju-
gate vaccine (PCV13, Prevnar-13, Pfizer, New York, NY, USA) replaced PCV7 for use 
during routine immunization in children (2), and by June 2013, the incidence of IPD, 
especially that caused by the PCV13 minus PCV7 serotypes, was further reduced across 
all age groups in the USA (3).
 In Korea, S. pneumoniae is the most common cause of invasive bacterial infections 
in immunocompetent children aged 3 months to 5 years (4). PCV7 was first introduced 
in Korea in November 2003 for optional use in the private sector, and the estimated 
PCV7 coverage rates among children aged 7-83 months increased from 44.8% to 73.8% 
for the 3-dose infant series and from 31.3% to 50.8% for the toddler dose from 2006 to 
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2010 (5). Although PCV7 was available as an optional immuni-
zation, a multicenter study between 2006 and 2010 revealed a 
significant reduction in the proportion of PCV7 serotypes and a 
significant increase in non-PCV7 serotypes (especially 19A) 
isolated from children with IPD (6). In June 2010, the 10-valent 
pneumococcal conjugate vaccine (PCV10, Synflorix®; GlaxoS-
mithKline, Brentford, London, UK) and PCV13 replaced PCV7 
in Korea. In May 2014, both PCV10 and PCV13 were included 
in the national immunization program for children under 60 
months of age. 
 The purpose of this study was to analyze the early changes in 
the serotype distribution of pneumococcus isolated from Kore-
an children with invasive disease during the 3-year period fol-
lowing the introduction of the 10- and 13-valent pneumococcal 
conjugate vaccines (PCVs) in Korea. 
MATERIALS AND METHODS
Study design
From January 2011 to December 2013, twenty-five hospitals lo-
cated throughout Korea participated in this study. Children un-
der 18 years of age with IPD were included in this study. IPD 
was defined as the isolation of S. pneumoniae from a normally 
sterile body fluid (e.g., blood, cerebrospinal fluid, pleural fluid, 
joint fluid, or ascites). A standardized case report form was used 
to collect information. The demographic data, comorbid disor-
ders, clinical diagnoses, and outcomes were collected. The co-
morbid disorders were classified according to the recommen-
dations of the Advisory Committee on Immunization Practices 
(ACIP). In the current study, the following conditions were con-
sidered risk factors for pneumococcal infection: chronic heart 
disease, chronic lung disease, cerebrospinal fluid leaks, cochle-
ar implants, functional or anatomic asplenia, and weakened 
immunity secondary to chronic renal failure and nephrotic syn-
drome, the administration of immunosuppressive drugs, or con-
genital immunodeficiency (2).
Serotype determination
A total of 75 pneumococcal isolates obtained from IPD patients 
were prospectively collected and subjected to serotype deter-
mination. Each isolate collected from participant centers was 
sent to the main study center (Seoul National University Chil-
dren’s Hospital), and serotype determination was performed 
using the Quellung reaction and antisera (Statens Serum Insti-
tut, Copenhagen, Denmark). One isolate failed to regrow, and 
the serotype was determined using 8 sequential multiplex poly-
merase chain reactions (PCRs) (7,8). As previously described, 
to assign serotypes 6C and 6D, all serogroup 6 strains were screen-
ed for the wciNβ and wciP genes (9).
 The serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, and 6A were classi-
fied as PCV7 types. The PCV13 minus PCV7 types included 5 
additional serotypes: 1, 3, 5, 7F, and 19A. The non-PCV13 types 
included all other serotypes (3,10).
 The serotype distribution was analyzed according to age, the 
presence of comorbid disorders, clinical diagnosis, and outcome. 
Trend analysis was performed by year.
Statistical analysis
The statistical analyses were performed using SPSS software 
version 22.0 (IBM, Armonk, NY, USA). The rates and propor-
tions were appropriately compared using either the χ2 test or 
Fisher’s exact test. For trend analysis, a linear-by-linear associa-
tion model was used in addition to the Pearson χ2 test. A P value 
< 0.05 was considered statistically significant.
Ethics statement
This study protocol was approved by the institutional review 
board of Seoul National University Hospital (IRB No. 1106-015-
364) as well as each participating hospital. Informed consent 
was confirmed by the IRB and was obtained from the patient 
and/or the guardian of the child. 
RESULTS
Patient characteristics
A total of 105 episodes of invasive pneumococcal infections was 
identified during the study period. Among these cases, 75 iso-
lates (71.4% of the total) were collected from consenting partici-
pants for inclusion in the study. The breakdown according to 
year was as follows: 24 cases in 2011, 33 cases in 2012, and 18 
cases in 2013.
 The male-female ratio in the current study was 1.08:1 (39:36). 
The percentage of patients separated by age group was 40.0% 
(30 cases) aged 0-23 months, 42.7% (32 cases) aged 24-59 months, 
and 17.3% (13 cases) aged ≥ 60 months. Twenty-four patients 
(32%) were at increased risk of pneumococcal infection (10 pa-
tients received immunosuppressive drugs, 4 had chronic heart 
disease, 3 had chronic renal failure or nephrotic syndrome, 2 
had congenital immunodeficiency, 2 had cerebrospinal fluid 
leak, 2 had cochlear implants, and 1 had chronic lung disease). 
The clinical diagnoses were pneumonia (i.e., bacteremic pneu-
monia or empyema; 28 cases), bacteremia without focus (22 
cases), meningitis (19 cases), osteoarthritis (4 cases), and peri-
tonitis (2 cases). Because 5 cases were transferred to other hos-
pitals not participating in this study, outcomes were known for 
only 70 patients. Fifty-five participants (78.6%) recovered with-
out complication, 10 participants (14.3%) had complications 
(i.e., hearing loss, developmental delay, or decreased pulmo-
nary function), and 5 participants (7.1%) died.
Serotype distribution of invasive pneumococcal isolates
The most common serotypes in the current study were 19A 
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(32.0%), 10A (8.0%), 15C (6.7%), 6A (5.3%), 11A (5.3%), 15B (5.3%), 
and 23A (5.3%). The PCV7 types accounted for 14.7% of the to-
tal isolates: serotype 6A (5.3%), 19F (2.7%), 23F (2.7%), 6B (1.3%), 
9V (1.3%), and 14 (1.3%). The PCV13 minus PCV7 types account-
ed for 32.0% of the total isolates; however, only serotype 19A 
was in this group. No isolates belonging to additional PCV10 
serotypes (1, 5, and 7F) were observed. The non-PCV13 types 
accounted for 53.3% of the total isolates (Table 1).
Temporal changes of serotype distribution
The proportion of isolates that were the PCV7 type was 16.7% in 
2011, 18.2% in 2012, and 5.6% in 2013. The proportion of PCV13 
minus PCV7 type (as noted above, serotype 19A was the only 
serotype identified in this study) decreased from 37.5% in 2011, 
to 33.3% in 2012 and to 22.2% in 2013; however, this trend was 
not statistically significant (P = 0.309). The proportion of non-
PCV13 types was 45.8% in 2011, 48.5% in 2012, and 72.2% in 
2013 (P for trend = 0.108) (Fig. 1). Among the non-PCV13 type 
isolates, the proportion of serotype 15C increased from 4.2% in 
2011 to 22.2% in 2013 (P = 0.036) (Table 1). 
Serotype distribution according to clinical characteristics
According to the age group, the proportion of non-PCV13 types 
exhibited no differences (50.0%-56.7%). However, when com-
paring the results from the group aged 0-23 months with the 
group aged 24-59 months, the proportion of PCV7 types (23.3% 
vs. 3.1%, P = 0.024) and PCV13 minus PCV7 types (20.0% vs. 
46.9%, P = 0.033) exhibited significant differences (Fig. 2).
 With respect to host comorbidity, among 51 participants not 
at risk of pneumococcal infection, PCV7 types and PCV13 mi-
nus PCV7 types accounted for 17.6% and 37.3%, respectively. 
The proportions were slightly lower among the 24 participants 
at increased risk of pneumococcal infection; the PCV7 types 
and PCV13 minus PCV7 types accounted for 8.3% and 20.8%, 
respectively. The proportions of non-PCV13 types were signifi-
cantly different: 45.1% among those without risk factors com-
pared with 70.8% among those with risk factors (P = 0.037). 
Among participants without risk factors for pneumococcal in-
Table 1. Serotype distribution of invasive pneumococcal isolates from children by 
year
Serotype
Year, No. (%)
Total
P for 
trend2011 2012 2013
PCV7 type 4 (16.7) 6 (18.2) 1 (5.6) 11 (14.7) 0.356
6B 1 (4.2) - - 1 (1.3) 0.216
9V 1 (4.2) - - 1 (1.3) 0.216
14 - 1 (3.0) - 1 (1.3) 0.914
19F - 2 (6.1) - 2 (2.7) 0.878
23F 2 (8.3) - - 2 (2.7) 0.078
6A - 3 (9.1) 1 (5.6) 4 (5.3) 0.365
PCV13 minus PCV7 type 9 (37.5) 11 (33.3) 4 (22.2) 24 (32.0) 0.309
19A 9 (37.5) 11 (33.3) 4 (22.2) 24 (32.0) 0.309
Non-PCV13 type 11 (45.8) 16 (48.5) 13 (72.2) 40 (53.3) 0.108
6C - - 1 (5.6) 1 (1.3) 0.147
10A 2 (8.3) 4 (12.1) - 6 (8.0) 0.388
11A 1 (4.2) 1 (3.0) 2 (11.1) 4 (5.3) 0.365
12F - - 1 (5.6) 1 (1.3) 0.147
13 1 (4.2) 1 (3.0) 1 (5.6) 3 (4.0) 0.850
15A 3 (12.5) 1 (3.0) - 4 (5.3) 0.066
15B 1 (4.2) 2 (6.1) 1 (5.6) 4 (5.3) 0.826
15C 1 (4.2) - 4 (22.2) 5 (6.7) 0.036
16F 1 (4.2) - - 1 (1.3) 0.216
23A 1 (4.2) 2 (6.1) 1 (5.6) 4 (5.3) 0.826
23B - 1 (3.0) 1 (5.6) 2 (2.7) 0.267
24F - 1 (3.0) - 1 (1.3) 0.914
33F - - 1 (5.6) 1 (1.3) 0.147
34 - 1 (3.0) - 1 (1.3) 0.914
35B - 1 (3.0) - 1 (1.3) 0.914
37 - 1 (3.0) - 1 (1.3) 0.914
Total 24 (100) 33 (100) 18 (100) 75 (100) -
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Fig. 1. Serotype distribution of invasive pneumococcal isolates from children accord-
ing to vaccine serotype by year.
*In PCV13 minus PCV7 types, only serotype 19A was recovered. 
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fection, 19A (37.3%), 10A (11.8%), 15C (9.8%), and 6A (7.8%) 
were the most common serotypes. However, serotypes 19A 
(20.8%), 11A (12.5%), and 15A (12.5%) were the most common 
serotypes in participants at increased risk of pneumococcal in-
fection (Fig. 3).
 The distribution of the serotypes was also analyzed accord-
ing to the clinical diagnoses. In the groups of patients with bac-
teremia without focus (n = 22), the PCV7, PCV13 minus PCV7, 
and non-PCV13 types accounted for 18.2%, 27.3%, and 54.5% 
of isolates, respectively. In the meningitis group (n = 19), the 
PCV7, PCV13 minus PCV7, and non-PCV13 types accounted 
for 15.8%, 5.3%, and 78.9% of isolates, respectively, and in the 
pneumonia group (n = 28), the PCV7, PCV13 minus PCV7, and 
non-PCV13 types accounted for 7.1%, 53.6%, and 39.3% of iso-
lates, respectively.
 There were 5 case fatalities: 2 deaths attributable to 19A and 
1 death attributable to each 6C, 10A, and 23A. The case fatality 
rate of serotype 19A infection was 8.7% (2 fatal cases among 23 
cases with known outcomes). 
DISCUSSION
This study reports the early changes in the IPD serotype distri-
bution among children during the 3-year period following the 
introduction of PCV10 and PCV13 as optional immunization in 
the Korean private sector. In addition to reporting the early im-
pact of these extended-valent vaccines, this study also surveyed 
the period before routine vaccination with PCV10 and PCV13 
in Korea. PCV10 and PCV13 were first introduced as optional 
immunizations in June 2010, and 4 years later, in May 2014, both 
vaccinations were included in the Korean national immuniza-
tion program. 
 From January 2011 to December 2013, 75 IPD cases from 25 
hospitals were included in this study. Eighty percent of the par-
ticipants with IPD were aged 3-59 months, and 32% of these 
participants had a comorbidity that predisposed them to pneu-
mococcal infection. The PCV7 types (including serotype 6A) 
accounted for 14.7% of the total isolates tested, and the PCV13 
minus PCV7 types accounted for 32.0% of the total isolates test-
ed. Serotype 19A was the only serotype found among the PCV13 
minus PCV7 types and was the most common serotype (32%). 
Although statistically insignificant, the proportion of serotype 
19A decreased from 37.5% in 2011 to 22.2% in 2013 (P = 0.309), 
and the proportion of non-PCV13 types increased from 45.8% 
in 2011 to 72.2% in 2013 (P = 0.108).
 In Korea, PCVs had been used as optional immunizations for 
11 years before PCV10 and PCV13 were made part of the na-
tional immunization program in 2014. Korea has been a unique 
environment for the development of pneumococcal infection. 
According to the results of a retrospective single-center study, 
the percentage of pediatric IPD cases caused by serotype 19A 
increased even prior to the introduction of PCV7 in 2003: from 
0% between 1991 and 1994 to 18% between 2001 and 2003. Some 
experts speculate that the increased incidence of pediatric IPD 
infection caused by serotype 19A may be associated with the 
antimicrobial selection pressure in Korea (11). After optional 
immunization with PCV7, a retrospective multicenter study 
suggested a decreased percentage of PCV7 isolates (excluding 
6A) from 62.5% in 2006 to 21.4% in 2010. Furthermore, the per-
centage of the PCV7 plus 6A types decreased from 65.6% in 2006 
to 28.6% in 2010, and the percentage of PCV13 minus PCV7 types 
(1, 3, 5, 7F, and 19A) increased from 18.8% in 2006 to 39.3% in 
2010. According to this same study, the proportion of serotype 
19A increased from 15.6% in 2006 to 35.7% in 2010 (6). The cur-
rent study, which examines the period after the introduction of 
optional immunization using PCV10 or PCV13 in 2010, dem-
onstrated a further decrease in the proportion of PCV7 types 
(plus 6A) from 16.7% to 5.6% and a decrease in the proportion 
of PCV13 minus PCV7 types (serotype 19A) from 37.5% in 2011 
to 22.2% in 2013.
 The impact of extended-valent PCVs, especially PCV13, has 
also been reported in other countries. In the United States three 
years after the introduction of PCV13, the incidence of IPD de-
creased by 64% among children younger than 5 years, with a 
93% decrease in the PCV13 minus PCV7 serotype. Additionally, 
the proportion of PCV13 minus PCV7 types changed from 59% 
to 28% (3). In England and Wales, the incidence of IPD decreas-
ed by 46% in groups aged < 2 years and 48% in those aged 2-4 
years. Additionally, the incidences of six other serotypes cov-
ered by PCV13 were 89% and 91%. The incidence of the addi-
tional six serotypes covered by PCV13 decreased from 59.4% to 
11.7%, four years after introduction of PCV13 (12). In the cur-
rent study, the proportion of the PCV13 minus PCV7 types in 
Korea was 37.3% from 2009 to 2010 (6) and decreased to 22.2% 
in 2013. This change is smaller than that observed in other coun-
tries, which may be because PCV was not initially included in 
the Korean national immunization program. As an optional 
Fig. 3. Serotype distribution of invasive pneumococcal isolates from children by co-
morbidity.
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form of immunization, parents choosing to have their children 
immunized with PCV were required to cover the full cost of the 
immunization. Thus, because of cost and lack of awareness, the 
PCV coverage rate was lower than that of vaccines included in 
national immunization program. Although we do not know the 
exact vaccination rates for each of PCV10 and PCV13 during 
2011-2013 in Korea, the overall PCV coverage rate in 2010 was 
73.8% for the infant series and 50.8% for the toddler dose and 
there should be no great change during the 3 year-study period 
when the vaccine were administered as an optional vaccine 
given in the private sector (5). Therefore, the impact of the vac-
cine might have been smaller than in other countries where the 
vaccine was routinely administered. 
 To support this, we tried to investigate the vaccination history 
of the patients with vaccine type pneumococcal infection. In 11 
cases with PCV7 serotype infection, 8 cases were known of vac-
cination history and all of them were incompletely vaccinated. 
In PCV13 minus PCV7 serotype infection, 19 out of 24 cases were 
known of vaccination history. Twelve cases were unvaccinated 
or vaccinated with only PCV7, and 4 cases were incompletely 
vaccinated with PCV13. Three cases were not at risk of pneumo-
coccal infection and were fully vaccinated according to ACIP 
guideline; 2 cases with 3 primary doses of PCV7 and 1 booster 
dose of PCV13, and 1 case with 4 doses of PCV7 and 1 supple-
ment dose of PCV13. Therefore, among 27 cases of PCV13 sero-
type pneumococcal infection with known vaccination history, 
there were no cases who received full (primary and booster) se-
ries of PCV13 vaccination.
 Also, according to the age group, the proportion of PCV13 mi-
nus PCV7 serotypes was highest in the group aged 24-59 months. 
This age group had more chance to get PCV7 other than extend-
ed-valent vaccines in the study period. Among the 32 IPD cases 
aged 24-59 months, 26 cases were known of vaccination history 
and 15 cases were unvaccinated or vaccinated with only PCV7, 
while 11 cases were vaccinated with at least one dose of PCV13. 
On other hands, among the 30 IPD cases aged 0-23 months, 26 
cases were known of vaccination history and 8 cases were un-
vaccinated, while 3 cases were vaccinated with PCV10 and 15 
cases were vaccinated with PCV13. 
 In the United States, the changes in pneumococcal serotypes 
after the introduction of PCV13 was also associated with change 
in the epidemiology of IPD clinical features. Furthermore, the 
incidence of pneumococcal meningitis remains unchanged, 
and pneumococcal meningitis accounts for a relatively larger 
proportion of IPD after the introduction of PCV13 (3,13). De-
creases in pneumonia and bacteremia, but not meningitis, were 
also reported in Spain (14). In our study, although there were 
fewer cases of meningitis than bacteremia or pneumonia, the 
proportion of non-PCV13 (78.9%) was the highest among men-
ingitis cases. This finding may suggest that following the contin-
ued administration of PCV13 the potential decrease in the inci-
dence of meningitis may be less than that of other diseases.
 Although the annual incidence of IPD caused by PCV13 types 
has decreased, there remains concern about the emergence of 
IPD due to non-PCV13 serotypes (12). Furthermore, there is an 
increase in the prevalence of underlying disorders contributing 
to illness among patients with IPD (3). Among patients with co-
morbidities associated with increased pneumococcal infection, 
several non-vaccine serotypes might emerge as important causes 
of IPD (15). Similar findings are observed in the current study; 
32% of IPD patients exhibited risk factors for pneumococcal in-
fection, and among these patients, the proportion of non-PCV13 
types (70.8%) was larger than that (45.1%) among those without 
increased risk. 
 This study has several limitations. First, this study was not 
population-based; therefore, only proportions of isolates were 
evaluated, and the incidence was not estimated. However, the 
25 centers included in this study are regional representative 
hospitals located throughout Korea; thus, we believe that the 
results of this study approximate the common pattern of pneu-
mococci serotype distribution among Korean children. Second, 
the study period was too brief to examine the trend of serotype 
changes after the introduction of extended-valent vaccine. Ad-
ditionally, the statistical power of the results was small. Howev-
er, to evaluate any further impact of routine immunization with 
PCV as recommended by the Korean national immunization 
program, understanding the pre-routine use of extended-valent 
vaccines was indispensable. Third, large proportions of missing 
pneumococcal isolates were noted (28.6% or 30 of 105 IPD cas-
es), which could represent a discrepancy between the current 
study and real-world findings. 
 However, despite these limitations, because Korea did not 
routinely survey pneumococcal infection before PCV was made 
part of the national vaccination program in 2014, the current 
study reports the most significant epidemiologic data examin-
ing pediatric IPD during the early period of optional use of ex-
tended-valent PCVs in Korea. Serotype 19A continued to be the 
most common serotype for IPD in children; however, the pro-
portion of 19A seemed to decrease, and non-vaccine serotypes 
seemed to emerge as an important cause of IPD. In the future, 
surveillance studies will be needed to evaluate the impact of 
PCVs, which are now a part of the national immunization pro-
gram in Korea. Additionally, efforts to develop more effective 
pneumococcal vaccines for children must continue. 
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